Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2021/03/031981
CTRI/2021/03/031981
Not yet recruiting
未知

Prevention of post-stroke seizures with Levetiracetam in Intracranial Cerebral Venous Sinus Thrombosis (PROLEVIS-CVT): A Randomized Placebo-Controlled Trial - PROLEVIS-CVT

DHRICMR0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
DHRICMR
Status
Not yet recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
DHRICMR

Eligibility Criteria

Inclusion Criteria

  • •Primary Prevention Arm
  • •1\. Adult patients (age \> 18 years) presenting with intracranial venous sinus thrombosis proven by CT/MRI brain and CT/MR Venography
  • •2\. Confirmation of diagnosis to randomisation within 14 days
  • •3\. No seizures at presentation
  • •Secondary Prevention Arm
  • •1\. Adult patients (age \> 18 years) presenting with intracranial venous sinus thrombosis proven by CT/MRI brain and CT/MR Venography
  • •2\. Confirmation of diagnosis to randomisation within 14 days
  • •3\. Early post stroke seizures ( \< 14 days)

Exclusion Criteria

  • •Primary Prevention Arm
  • •1\.Previous history of epilepsy or treatment with an AED
  • •2\.Seizure or status epilepticus at onset of stroke or prior to recruitment
  • •3\.Known allergy to Levetiracetam
  • •4\.Pregnant women
  • •5\.Chronic renal failure
  • •Secondary Prevention Arm
  • •1\.Previous history of epilepsy or treatment with an AED
  • •2\.Status epilepticus at onset of stroke or prior to recruitment
  • •3\.Known allergy to Levetiracetam

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 3
Prophylactic antiseizure medication in post cardiac arrest childreHealth Condition 1: R00-R99- Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
CTRI/2024/05/067855All India Institute of Medical Sciences Raipur
Active, not recruiting
Phase 1
Prophylactic treatment of stroke patients with eslicarbazepine acetate to prevent the development of epilepsy
EUCTR2018-002747-29-SEBial - Portela & Ca, S.A.220
Active, not recruiting
Phase 1
Prophylactic treatment of stroke patients with eslicarbazepine acetate to prevent the development of epilepsy
EUCTR2018-002747-29-PTBial - Portela & Ca, S.A.220
Active, not recruiting
Phase 1
Prophylactic treatment of stroke patients with eslicarbazepine acetate to prevent the development of epilepsy
EUCTR2018-002747-29-ESBial - Portela & Ca, S.A.220
Active, not recruiting
Phase 1
Prophylactic treatment of stroke patients with eslicarbazepine acetate to prevent the development of epilepsyAdult patients at high-risk to develop post-stroke epilepsyMedDRA version: 22.1Level: PTClassification code 10076982Term: Post stroke epilepsySystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2018-002747-29-ITBIAL-Portela & Ca, S.A.220